Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 6Gynecologic 4Plasma cell 3Gastrointestinal 2Thoracic 1Lymphoid 1Genitourinary 1

Conditions

Lymphoma, Large B-Cell, Diffuse 10Lymphoma 7Lymphoma, Follicular 5Lymphoma, Non-Hodgkin 4Lymphoma, T-Cell, Cutaneous 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Melanoma 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Carcinoma, Merkel Cell 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Testicular Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Sarcoma 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1

Interventions

Cyclophosphamide 100Rituximab 82fludarabine phosphate 46Peripheral Blood Stem Cell Transplantation 45fludarabine 43Lenalidomide 35Filgrastim 33Methotrexate 32Cytarabine 32Busulfan 32venetoclax 31Etoposide 31Cyclosporine 30Dexamethasone 29Radiotherapy 28Mycophenolic Acid 28Melphalan 28Bendamustine Hydrochloride 25Antilymphocyte Serum 25Vincristine 24Gemcitabine 24ibrutinib 22Whole-Body Irradiation 22Doxorubicin 20Tacrolimus 19Methylprednisolone 18Bortezomib 18Brentuximab Vedotin 16pembrolizumab 15Prednisone 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × durvalumab × Lymphoid × Clear all
NCT03323398 2024-07-31

Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

ModernaTX, Inc.

Phase 1/2 Terminated
79 enrolled 18 charts
GynecologicLymphoid

Lymphoma, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡